Document Detail

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.
MedLine Citation:
PMID:  16305055     Owner:  NLM     Status:  MEDLINE    
Congestive heart failure (CHF) is a serious disease with a poor prognosis. Diabetes is an independent risk factor for CHF, probably in part due to disturbances in myocardial metabolism. Glucagon-like peptide-1 (GLP-1) causes glucose-dependent secretion of insulin, improving glycaemic control. In turn, this may improve myocardial metabolism and myocardial function. The aim of the present study was to assess the feasibility and safety of three days' infusion of recombinant GLP-1 in an open observational study in six patients with type 2 diabetes and CHF. The study included assessment of myocardial function. There were no major complications of the infusion, and all patients completed the study protocol. Some improvement was observed in glycaemic state, and there was an insignificant trend towards improved myocardial function. It is concluded that GLP-1 deserves further evaluation in such patients.
Inga Thrainsdottir; Klas Malmberg; Arne Olsson; Mark Gutniak; Lars Rydén
Related Documents :
14759095 - New-onset congestive heart failure secondary to a "huge" right atrial mass--a case report.
3094955 - Transcatheter treatment of myelomatous av shunting causing high-output failure.
12042685 - Hemodynamic responses during aerobic and resistance exercise.
17905165 - Congestive heart failure and cardiovascular death in patients with prediabetes and type...
22743635 - Cardiac autophagy: good with the bad.
7355 - Effects of angiographic contrast media on sino-atrial nodal function.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease     Volume:  1     ISSN:  1479-1641     ISO Abbreviation:  -     Publication Date:  2004 May 
Date Detail:
Created Date:  2005-11-24     Completed Date:  2005-12-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101234011     Medline TA:  Diab Vasc Dis Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  40-3     Citation Subset:  IM    
Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / drug effects
C-Peptide / blood
Diabetes Mellitus, Type 2 / blood,  complications*,  drug therapy
Echocardiography, Doppler
Exercise Test
Glucagon / blood
Glucagon-Like Peptide 1 / administration & dosage,  therapeutic use*
Heart / drug effects*,  physiology
Heart Failure / blood,  drug therapy*,  etiology
Infusions, Parenteral
Injections, Subcutaneous
Insulin / blood
Myocardial Contraction / drug effects
Pilot Projects
Recombinant Proteins / therapeutic use
Time Factors
Reg. No./Substance:
0/Blood Glucose; 0/C-Peptide; 0/Recombinant Proteins; 11061-68-0/Insulin; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors.
Next Document:  Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle siz...